Shots:
- Abbott has reported CE Mark approval of TactiFlex Duo Ablation Catheter, Sensor Enabled to treat pts with atrial fibrillation (AF)
- Approval was based on the global FOCALFLEX CE Mark study assessing TactiFlex Duo, which showed clinically meaningful efficacy & favorable safety in the AF pts
- Also being evaluated in the FLEXPULSE IDE trial in the US, TactiFlex Duo delivers tailored therapy lesions using both RF & PFA energy & integrates with Abbott’s EnSite X EP System to create detailed 3D heart maps to help identify & treat arrhythmia sources
Ref: Abbott | Image: Abbott | Press Release
Related News: Abbott Reports FDA Clearance and CE Mark Approval of its Amplatzer Piccolo Delivery System for Premature Babies with a Hole in the Heart
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
